SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Netflix, Inc. engages in providing entertainment services. It also offers activities for leisure time, entertainment video, video gaming, and other sources of entertainment. It operates through the United States and International geographic segments. The company was founded by Marc Randolph and Wilmot Reed Hastings on August 29, 1997 and is headquartered in Los Gatos, CA.

Netflix Inc.

Netflix Inc

Netflixs Q3 earnings report is the dominant focus, with traders watching managements outlook on subscriber engagement, growth and advertising amid a steep share-price decline. Views are split: bears fear continued weakness and content concerns, while bulls argue expectations are low and a solid outlook could support a rebound.

Sea Ltd. is an internet and mobile platform company, which engages in the provision of online gaming services. It operates through the following segments: Digital Entertainment, E-Commerce, and Digital Financial Services. The Digital Entertainment segment offers and develops mobile and PC online games. The E-Commerce segment manages a third-party marketplace through the Shopee mobile app and websites that connect buyers and sellers. The Digital Financial Services segment includes a variety of payment services and loans to individuals and businesses through SeaMoney. Sea was founded by Xiao Dong Li, Gang Ye, and Jing Ye Chen on May 8, 2009 and is headquartered in Singapore.

Sea Ltd - ADR

Sea is selling off amid trader concerns that its planned Sea Cloud launch and a potential Monee public listing could add uncertainty and spending pressure while Shopee faces subsidy competition from TikTok Shop and Temu. The community is divided over whether the decline is an overreaction to those plans or a sign of deeper competitive and profitability concerns.

SELLAS Life Sciences Group, Inc. is a clinical stage biopharmaceutical company, which engages in the development and commercialization of immunotherapeutic for cancer indications. Its product pipeline includes galinpepimut-S. The company was founded by Angelos M. Stergiou on April 3, 2006 and is headquartered in New York, NY.

SELLAS Life Sciences Group Inc

SLS is drawing attention as traders anticipate the 80-event trigger for final analysis of SELLASs Phase 3 REGAL trial; the last disclosed count cited in the discussion was 78. CEO Angelos Stergious anniversary message has also fueled unconfirmed buyout speculation, while skeptics stress that no trial update or deal is confirmed and attribute the rebound to trading and biotech-sector strength.

GE Aerospace is an American aircraft company, which engages in the provision of jet and turboprop engines, as well as integrated systems for commercial, military, business, and general aviation aircraft. The firm's portfolio of brands includes Avio Aero, Unison, GE Additive, and Dowty Propellers. It operates through the following segments: Commercial Engines and Services, Defense and Propulsion Technologies, and Corporate and Other. The Commercial Engines and Services segment is involved in the design, development, manufacturing, and servicing of jet engines for commercial airframes, as well as business aviation and aeroderivative applications. The Defense and Propulsion Technologies segment offers defense engines and critical aircraft systems. The Corporate and Other segment relates to corporate functions and operations costs. The company was founded by Thomas Alva Edison in 1878 and is headquartered in Evendale, OH.

GE Aerospace

GE Aerospaces earnings beat and raised outlook have been overshadowed by a sharp selloff, with traders pointing to rising costs, weaker cash conversion, and an insurance-business loss as concerns about profitability. The reaction has frustrated bullish holders, while others see the pullback as a buying opportunity and note that strong orders and demand remain intact.

Sarepta Therapeutics, Inc. is a commercial-stage biopharmaceutical company, which is engaged in the discovery and development of therapeutics for the treatment of rare diseases. The company was founded on July 22, 1980 and is headquartered in Cambridge, MA.

Sarepta Therapeutics Inc

Anticipation of Sareptas DM1 and FSHD siRNA data is driving discussion, with traders pointing to positive Arrowhead results and Sareptas preclinical DM1 findings as support for the platform. Others caution that optimism and suspected short covering are not substitutes for human readouts, and debate whether the share move reflects company-specific momentum or broader biotech strength.

Myriad Genetics, Inc. is a molecular diagnostics and precision medicine company committed to advancing health and well-being for all. It develops and commercializes molecular tests that help patients and providers uncover genetic insights. The company was founded by Walter A. Gilbert, Mark H. Skolnick, and Peter D. Meldrum in May 1991 and is headquartered in Salt Lake City, UT.

Myriad Genetics, Inc.

Myriads agreement to sell its prenatal testing business to Labcorp is driving a sharp rally, with traders viewing the cash proceeds as a way to strengthen the balance sheet and refocus on oncology. Others are cautious that the divestiture also removes a significant revenue stream from a company already facing business and profitability concerns.

General Motors Co. engages in the designing, manufacturing, and selling of trucks, crossovers, cars, and automobile parts, and in providing software-enabled services and subscriptions. It operates through the following segments: GMNA, GMI, Cruise, and GM Financial. The company was founded by William C. Durant on September 16, 1908 and is headquartered in Detroit, MI.

General Motors Company

GMs quarterly earnings beat and new buyback were overshadowed by a narrowed full-year profit outlook with the midpoint unchanged, prompting a sharp selloff. Traders are divided between buying the dip on stronger cash-flow prospects and seeing the guidance as a reason for the stocks decline.

Rapport Therapeutics, Inc. engages in the discovery and development of transformational small molecule medicines for patients suffering from central nervous system disorders. It develops the RAP (receptor associated proteins) technology platform. The company was founded by Steven M. Paul and David Bredt in February 2022 and is headquartered in Boston, MA.

Rapport Therapeutics Inc.

Rapport Therapeutics Inc

Rapports attention is centered on Phase 2 results for RAP-219 in bipolar mania, which traders say met the primary and secondary endpoints and prompted bullish reactions and analyst upgrades. The response is divided: skeptics question the modest efficacy signal and point to agitation events and higher discontinuations, while shares have shown sharp volatility after the initial enthusiasm.

Northrop Grumman Corp. engages in the provision of advanced aircraft systems. It operates through the following segments: Aeronautics Systems, Defense Systems, Mission Systems, and Space Systems. The Aeronautics Systems segment is involved in the design, development, production, integration, sustainment, and modernization of advanced aircraft systems for the U.S. Air Force, the U.S. Navy, other U.S. government agencies, and international customers. The Defense Systems segment includes integrated battle management systems, weapons systems and aircraft, and mission systems sustainment and modernization. The Mission Systems segment offers advanced mission solutions and multifunction systems, primarily for the U.S. defense and intelligence community, and international customers. The Space Systems segment delivers end-to-end mission solutions through the design, development, integration, production and operation of space, missile defense, launch and strategic missile systems for national security, civil government, commercial, and international customers. The company was founded by John K. Northrop, Thomas V. Jones, and Kent Kresa in 1939 and is headquartered in Falls Church, VA.

Northrop Grumman Corp.

Northrop Grummans strong third-quarter results, raised 2026 earnings outlook and record backlog are driving the move higher. Traders are broadly bullish on the earnings and defense-demand outlook, though some are watching whether the shares can hold their gains after the jump.

The Compound Governance Token is a governance token on the Compound Finance lending protocol, COMP allows the owner to delegate voting rights to the address of their choice; the owner’s wallet, another user, an application, or a DeFi expert. Anybody can participate in Compound governance by receiving delegation, without needing to own COMP.  Anybody with 1% of COMP delegated to their address can propose a governance action; these are simple or complex sets of actions, such as adding support for a new asset, changing an asset’s collateral factor, changing a market’s interest rate model, or changing any other parameter or variable of the protocol that the current administrator can modify.

Compound

COMPs sharp rally has sparked breakout and short-squeeze speculation, with traders pointing to bullish chart patterns and the tokens limited supply. Some see it as a catch-up move after prolonged underperformance, while others remain skeptical and want a clearer catalyst; the institutional push and planned V4 are cited as longer-term bullish context.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Pulse Biosciences Announces Commercial and Clinical Partnership with the Clayman Thyroid Center

Pulse Biosciences, Inc. (Nasdaq: PLSE), the company leveraging its ever evolving novel and proprietary Nanosecond Pulsed Field Ablation (nano-PFA or nsPFA) technology, today announced a partnership with the Clayman Thyroid Center at the Hospital for Endocrine Surgery in Tampa, Florida. The...

Pulse Biosciences Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Pulse Biosciences, Inc. (Nasdaq: PLSE), the company leveraging its ever evolving novel and proprietary Nanosecond Pulsed Field Ablation (nano-PFA or nsPFA) technology, today announced that the Compensation Committee of its Board of Directors has granted equity awards to two new employees as equity...

Pulse Biosciences nPulse Technology to be Featured at the 21st Annual International VT Symposium 2026

Pulse Biosciences, Inc. (Nasdaq: PLSE), the company leveraging its ever evolving novel and proprietary Nanosecond Pulsed Field Ablation (nano-PFA or nsPFA) technology, today announced the latest nPulse technology advancement will be featured during the 21st Annual International Ventricular...

Pulse Biosciences Achieves Enrollment Target in NANOPULSE-AF IDE Pivotal Clinical Study Evaluating nPulse Cardiac Catheter System for Atrial Fibrillation Treatment

Pulse Biosciences, Inc. (Nasdaq: PLSE), a company leveraging its novel and proprietary Nanosecond Pulsed Field Ablation (nano-PFA or nsPFA) technology, today announced that its NANOPULSE-AF Study has reached its enrollment target of 164 evaluable patients across 15 clinical sites. "The compelling...

Pulse Biosciences Completes Enrollment in the PRECISE-BTN Clinical Study Evaluating the nPulse Vybrance Percutaneous Electrode System for Symptomatic Benign Thyroid Nodules

Pulse Biosciences, Inc. (Nasdaq: PLSE), developer of the novel nPulse technology using proprietary Nanosecond Pulsed Field Ablation (nanosecond PFA or nsPFA) energy, today announced two milestones in the PRECISE-BTN clinical study evaluating the nPulse Vybrance Percutaneous Electrode System for the...

Why Pulse Biosciences Stock Popped Today

Key PointsAn analyst initiated coverage with an unambiguous buy recommendation...

Pulse Biosciences, Inc. (Nasdaq: PLSE), a company leveraging its novel and proprietary Nanosecond Pulsed Field Ablation (nano-PFA or nsPFA) technology, today announced that the Compensation Committee of its Board of Directors has granted equity awards to two new employees as equity inducement...

Pulse Biosciences, Inc. (Nasdaq: PLSE), a company leveraging its novel and proprietary Nanosecond Pulsed Field Ablation (nano-PFA or nsPFA) technology, today announced that the Compensation Committee of its Board of Directors has granted equity awards to five new employees as equity inducement...

Pulse Biosciences (PLSE) Q2 2026 Earnings Call Transcript

@media (max-width: 768px) {
 .image-container {
 width: 100% !important;
 float: none !important;
 margin: 0 0 1rem 0 !important;
 }
 }

Image source: The Mo...

Pulse Biosciences, Inc (PLSE) Reports Q2 Loss, Misses Revenue Estimates

Pulse Biosciences (PLSE) delivered earnings and revenue surprises of -16.13% and -38.00%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?

Pulse Biosciences, Inc. operates as a novel bioelectric medicine company. It offers nPulse System, a novel Nanosecond Pulsed-Field Ablation delivery platform to treat benign lesions of the skin; nPulse Vybrance Percutaneous Electrode system for soft tissue ablation in surgical setting; nPulse Cardiac Surgical Clamp designed for use in surgical treatment of atrial fibrillation (AF); nPulse Cardiac Catheter System designed to provide a circumferential, or circular, ablation in a single treatment cycle; and nPulse Console, a software-enabled console-based platform designed to accommodate the clinical workflow preferred by physicians. The company was formerly known as Electroblate, Inc. and changed its name to Pulse Biosciences, Inc. in December 2015. Pulse Biosciences, Inc. was incorporated in 2014 and is headquartered in Miami, Florida.

Pulse Biosciences Inc

Bullish Sentiment

Double beat (rev + EPS)

Revenue beat, EPS miss

EPS beat, revenue miss

Double miss

SpaceX ($SPCX) reports earnings after the close today. What do you expect?

Stocktwits

SpaceX

) reports earnings after the close today. What do you expect?

Stocktwits Polls

$PLSE Does anything think Duggan will start buying if it goes below $40 or $30? Or was $20 his max price? Never know what goes on in these billionaires minds lol

Ryker Jones

$PLSE Please try harder WhiteResearch missed  the COO’s open-market buys around $48–50 while calling disclosed analyst meetings a secret dump. Duggan and the CEO haven’t bought above the May $19.69 prints—that part holds. No one on his list is even looking to short it. Your sorry attempt to mislead spread false information is sad  - and on top of that you're the same clowns that tried this last time with false information lol

Feed

News

Sentiment

Earnings

Fundamentals

Info

PLSE Pulse Biosciences Inc

Fundamentals

Latest PLSE News